| 9.81 0.16 (1.66%) | 11-28 13:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.4 | 1-year : | 15.05 |
| Resists | First : | 11.48 | Second : | 12.89 |
| Pivot price | 10.33  |
|||
| Supports | First : | 9.19 | Second : | 7.65 |
| MAs | MA(5) : | 9.67 |
MA(20) : | 10.55 |
| MA(100) : | 11.59 |
MA(250) : | 10.92 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 11.3 |
D(3) : | 9.4 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 17.43 | Low : | 5.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRMD ] has closed above bottom band by 31.0%. Bollinger Bands are 7.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.68 - 9.75 | 9.75 - 9.8 |
| Low: | 9.21 - 9.28 | 9.28 - 9.34 |
| Close: | 9.56 - 9.67 | 9.67 - 9.75 |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Thu, 27 Nov 2025
At Cormedix, Janet Dillione Chooses To Exercise Options, Resulting In $158K - Benzinga
Thu, 27 Nov 2025
CorMedix director Dillione sells $261,585 in CRMD stock By Investing.com - Investing.com South Africa
Wed, 26 Nov 2025
CorMedix (CRMD) Is Down 6.3% After Strong Q3 Results and $87.6M Shelf Registration Filed - simplywall.st
Wed, 26 Nov 2025
CorMedix (CRMD) Is Down 6.3% After Strong Q3 Results and $87.6M Shelf Registration Filed - Sahm
Tue, 18 Nov 2025
Dillione Janet sells CorMedix (CRMD) shares for $342,600 - Investing.com
Tue, 18 Nov 2025
Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 79 (M) |
| Shares Float | 73 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 54.7 (%) |
| Shares Short | 16,600 (K) |
| Shares Short P.Month | 15,560 (K) |
| EPS | 2.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.78 |
| Profit Margin | 75.8 % |
| Operating Margin | 49.2 % |
| Return on Assets (ttm) | 15.6 % |
| Return on Equity (ttm) | 75 % |
| Qtrly Rev. Growth | 810.2 % |
| Gross Profit (p.s.) | 2.56 |
| Sales Per Share | 2.71 |
| EBITDA (p.s.) | 1.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 75 (M) |
| Levered Free Cash Flow | 17 (M) |
| PE Ratio | 4.43 |
| PEG Ratio | 0 |
| Price to Book value | 2.05 |
| Price to Sales | 3.6 |
| Price to Cash Flow | 10.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|